Introduction
A number of targeted drugs have been developed to clinical approval in recent years. Other drugs are in advanced stages of development. They include inhibitors of the PI3K/Akt-kinase signaling pathway, such as mTOR (mammalian target of rapamycin) inhibitors and PI3K (phosphatidylinositol 3-kinase) inhibitors, inhibitors of the PARP (poly [ADP-ribose] polymerase) enzyme, immunomodulators such as antibodies against PD-1 (programmed cell death protein-1) and PD-L1 (programmed cell death protein-1/ ligand-1) and, not least, CDK (cyclin-dependent kinase) 4/6 inhibitors, which inhibit the cell cycle in hormone receptor-positive cancer. These drugs are a consequence of the growing understanding of both cellular functions and the genetics of cancers and of patientsʼ hereditary genetics. This article summarizes new data publicized in 2017 at the two big international conferences ASCO and ESMO, focuses particularly on the most recent medical therapies for patients with breast cancer.
Neoadjuvant Therapy
Treating patients with primary breast cancer prior to surgery (i.e., neoadjuvant therapy) continues to be hugely important in routine treatment, the development of new drug therapies and the modification of existing therapy concepts. While it has been possible to establish a link between pathological complete remission (pCR) and excellent prognosis for some molecular subtypes (triple-negative, HER2-positive), this association has not been clearly proven for hormone receptor-positive, HER2-negative breast cancer [1, 2] . There are some indications that the link between pCR and prognosis in certain molecular groups, e.g. patients with BRCA (breast cancer gene) mutations, is not as pronounced as when these molecular changes are not present [3] . It is therefore particularly interesting to see how pronounced the connection between pCR and prognosis is in the most recent studies.
In this context this year saw the presentation of updated survival data from the NeoALTTO study [4] . With a median follow-up of 6.7 years, the study confirmed that, irrespective of the therapy, pCR is an excellent predictor of recurrence-free survival and overall survival for HER2-positive breast cancer. The study which compared neoadjuvant therapy with paclitaxel plus either lapatinib, lapatinib + trastuzumab or trastuzumab, was not able to show any differences in survival variables [4] , despite the differences in pCR [5] . The final survival data from the similar GeparQuinto trial [6] have not yet been published.
The GeparSixto trial [7] , which evaluated the benefits of adding carboplatin to anthracycline-based and taxane-based chemotherapy to treat patients with triple-negative and HER2-positive primary cancer, was able to show the effect of therapy on pCR and on the subsequent prognosis. The addition of carboplatin significantly improved the prognosis of patients with triple-negative breast cancer (HR = 0.56 [95 % CI: 0.34-0.93]; p = 0.024) but had no significant impact on HER2-positive breast cancer [8] . Platinum-based treatment should therefore increasingly become standard treatment in the neoadjuvant setting for patients with triplenegative breast cancer.
In the GeparOcto trial, one arm of the trial compared platinumbased chemotherapy (weekly paclitaxel, liposomal doxorubicin and carboplatin) with dose-dense chemotherapy with epirubicin, paclitaxel and cyclophosphamide (ETC regimen) in triple-nega-cancer. Digital communications between patients and physicians are being evaluated in several studies in Germany. As the discussion about patient-relevant endpoints for patients in the metastatic setting continues, overall survival rates from studies of big endocrine-based therapies are urgently needed. Preliminary analyses of small study cohorts offer initial insights. In the context of improving patient care, in the coming years, questions will center on which patients particularly benefit from certain therapies and which patients need particular protection from specific side effects. Questions about these predictors are raised in many scientific projects as attention increasingly focuses on this topic. tive, HER2-positive and high-risk hormone receptor-positive/ HER2-negative patients. HER2-positive patients additionally received dual therapy with trastuzumab and pertuzumab. No differences were found in pCR rates [9] . The survival data have not yet been published.
ZUSAMMENFASSUNG
A neoadjuvant study which contained the anti-PD-1 antibody pembrolizumab is described below in the chapter "Immuno-Oncology".
The development of therapies often requires testing for molecular markers. While testing for hormone receptor status and HER2 status often only takes a few days, testing for other markers such as BRCA1/2 mutations or for characteristics often summarized by the term "homologous repair deficiency (HRD)" can take several weeks. The question then arises whether the wait to obtain a precise molecular characterization could worsen the prognosis of women with breast cancer. An analysis of more than 8000 women with breast cancer did not find that the time between diagnosis and the start of neoadjuvant chemotherapy or the time between the end of chemotherapy and surgery had an impact on recurrence-free survival or overall survival as long as the cut-off was 4 weeks [10] . This indicates that there is no obstacle to carrying out more comprehensive molecular testing, even if it takes longer than determining hormone receptor and HER2 status. The GeparOLA trial, which is currently still recruiting and randomizes patients with BRCA1/2 germline mutations or tumors and patients with identified HRD for chemotherapy with or without the PARP inhibitor olaparib, has adopted this approach [11] .
Adjuvant Therapy
Researchers are keenly awaiting data from the APHINITY trial, one of the biggest currently running adjuvant therapy trials with antibodies [12, 13] . This German-led trial is investigating the effect of pertuzumab in addition to treatment with trastuzumab, as previous studies appeared to indicate that in the metastatic and neoadjuvant setting pertuzumab combined with trastuzumab and chemotherapy was more effective than trastuzumab and chemotherapy alone. In the metastatic setting, the addition of pertuzumab significantly improved both recurrence-free survival (18.5 vs. 12.4 months) and overall survival (56.5 vs. 40.8 months) [14, 15] . In the neoadjuvant setting, the NeoSphere trial showed a rise in the pCR rate (ypT0/ypN0) from 23 to 42 % [16] . Based on these data, the APHINITY trial was initiated, with more than 4800 participants. Randomization was done 1 : 1 with patients randomized to receive standard chemotherapy with trastuzumab or dual antibody therapy with the addition of pertuzumab. Primary endpoint of the study was invasive recurrence-free survival. Although the overall prognosis for both treatment arms was excellent, the trial still showed a small but significant benefit when pertuzumab was added. After a median follow-up of 45 months, 210 events (invasive 4-year DFS: 90.6 %) had occurred in the trastuzumab arm while 171 events (invasive 4-year DFS: 92.3 %) had occurred in the pertuzumab-trastuzumab arm. This resulted in a hazard ratio of 0.81 (95 % CI: 0.66-1.00; p = 0.045) [12, 13] . The clinical importance of these data and the question whether pertuzumab should be administered to the total study population or to special sub-groups (e.g. with node-positive, hormone receptor-negative cancers) will need to be discussed in the context of its approval for use.
Other anti-HER2 substances are also being tested in the adjuvant setting. Results from the ExteNET trial with a follow-up of 2 years have already been published [17] and showed an improvement in invasive recurrence-free survival when patients with HER2-positive breast cancer who had had one year of treatment with trastuzumab were subsequently treated with the small molecule neratinib for one year. The 5-year survival rates were published at this yearʼs ESMO 2017 conference [18] . With a hazard ratio of 0.78 (95 % CI: 0.57-0.92; p = 0.008) the results were similar to those in the initial publication (HR = 0.67). Researchers are currently awaiting the approval of further trials. It will be necessary to develop strategies to identify those patient characteristics which indicate that patients with these characteristics should receive the expanded targeted therapy. A subgroup analysis showed a particular benefit for hormone receptor-positive patients.
New Treatment Options in the Metastatic Setting

CDK4/6 inhibitors
In the last two years, a wealth of data has been published on the use of CDK4/6 inhibitors to treat patients with hormone receptorpositive, HER2-negative metastatic breast cancer [19 -22] . Up to now, data were only available for the CDK4/6 inhibitors palbociclib and ribociclib, both of which have been approved for use in Germany. However, this year, data on the CDK4/6 inhibitor abemaciclib was presented at the 2017 ASCO and ESMO conferences [23 -26] . While the MONARCH 2 trial included patients, who had recurrence during neoadjuvant or adjuvant endocrine therapy or within 12 months of completing therapy, the MONARCH 3 trial focused on patients who had not yet received systemic therapy for advanced or metastatic disease.
In the MONARCH 2 trial patients were randomized into treatment with fulvestrant or treatment with fulvestrant + abemaciclib. Progression-free survival (PFS) with monotherapy was 9.3 months, but PFS survival was increased to 16.4 months with the combination therapy (HR = 0.553; 95 % CI: 0.449-0.681; p < 0.001). Subgroup analysis found no particular group which benefited especially well or less well from therapy with abemaciclib. The most common side effect of treatment with abemaciclib was neutropenia (grade 3 and 4), which occurred in 23.6 % of patients compared with 1.3 % in the group of patients who received fulvestrant monotherapy. Diarrhea (grade 3 and 4) was the second most common side effect in the group which received fulvestrant + abemaciclib, affecting 13.4 % of patients compared to just 0.4 % of patients in the group which received fulvestrant monotherapy [24] .
The MONARCH 3 trial randomized patients to receive either treatment with a non-steroidal aromatase inhibitor (nsAI; anastrozole or letrozole) or treatment with nsAI + abemaciclib. The addition of abemaciclib significantly extended PFS (HR = 0.54; 95 % CI: 0.41-0.72; p = 0.00021). While the median PFS with fulvestrant was 14.7 months, the median PFS has not yet been reached for treatment with nsAI + Abemaciclib [24] . A subgroup analysis in this study also did not find any group of patients who benefited especially from treatment. The side-effect profile was similar to that reported in the MONARCH 2 trial (9.5 % grade 3 and 4 diarrhea; 21.1 % grade 3 and 4 neutropenia) [24] .
Even though many studies have demonstrated the significant benefits of CDK4/6 inhibitors with regard to PFS [20 -24] , data on overall survival (OS) are currently still lacking. Overall survival results have been reported for the PALOMA 1 trial and the MONA-LEESA 2 trial but have not yet been published in full (▶ Figs. 1 and  2) . At the ASCO 2017 conference, the PALOMA 1 trial, which only randomized 165 patients and received provision approval in the USA based on this data, reported a median OS of 34.5 months for letrozole alone and median OS of 37.5 months for letrozole combined with palbociclib [27] . The hazard ratio was 0.897 (95 % CI: 0.623-1.294; p = 0.281) [27] . Analysis in the MONALEESA 2 trial showed that the median OS time had not yet been reached. With an HR of 0.746 (95 % CI: 0.517-1.076; p = 0.059) the trial currently still just misses statistical significance [28] . Data which would show an overall survival benefit are therefore still lacking. It should, however, be noted that all of these studies are underpowered regarding a median OS of around 50 months which is currently achieved in several current studies of women with hormone receptor-positive metastatic breast cancer [29, 30] .
Therapies with CDK4/6 inhibitors have prompted a renewed discussion about patient-relevant endpoints. The most intensely discussed issue in this context is whether overall survival is the only relevant objective of a study or would a significant benefit with regard to progression-free survival be sufficient? In their latest presentation of the PALOMA 1 trial, Finn et al. also presented an analysis of the time to first chemotherapy following randomization. They were able to show that the time to chemotherapy increased significantly from a median of 17.7 months with letrozole to 26.7 months with letrozole + palbociclib (HR = 0.662 [95 % CI: 0.445-0.989, ▶ Fig. 3] ). Based on the existing data and the clinically relevant significant extension of PFS, the use of CDK4/6 inhibitors has become standard to treat hormone receptor-positive metastatic breast cancer, which is reflected in the guidelines and recommendations.
Homologous repair deficiency: patient-oriented therapies and other hereditary panel genes
BRCA1 and BRCA2 are DNA repair genes. They are involved in the repair of DNA double-strand breaks (homologous repair). PARP (poly [adenosine diphosphate ribose]) enzymes are essential for the repair of DNA single-strand breaks [31] . In the preclinical stage, cancer cells with a BRCA1/2 mutation are sensitive to PARP inhibitors. The hypothesis is that in women with BRCA1/2 mutation, the additional inhibition of another DNA repair mechanism leads to synthetic lethality. PARP inhibitors which are either in clinical development or have already been approved include talazoparib (BMN673 or MDV3800), olaparib (AZD2281 or KU-0059436), niraparib (MK4827), veliparib (ABT888) and rucaparib Fig. 1 Overall survival in the PALOMA 1 trial, modified according to [27] . Fig. 2 Overall survival in the MONALEESA 2 trial, modified according to [28] . Fig. 3 Time to chemotherapy in the PALOMA 1 trial, modified according to [27] .
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(AG-014699 or PF-01367338). In the USA and Europe olaparib has already been approved to treat certain patients with ovarian cancer (with BRCA1/2 mutations and platinum-sensitive recurrence). The PARP inhibitor niraparib has been approved for use in the USA to treat women with platinum-sensitive ovarian cancer recurrence irrespective of whether patients have BRCA mutation or not. The European Medicines Agency has also already voted in favor of extending the approval. Outcomes from the OlympiaD trial, an olaparib approval study for metastatic breast cancer [32, 33] , were presented at the ASCO 2017 conference. The study randomized 302 patients with germline BRCA1 or BRCA2 mutations. For inclusion in the study, patients should not have had more than 2 previous chemotherapies. Hormone receptor-positive patients had to have had at least one line of endocrine therapy [32] . The trial compared monotherapy with olaparib (2 : 1 randomization) with a chemotherapy chosen by the treating physician (either capecitabine, eribulin or vinorelbin). In this patient population, which per se had a poor prognosis, the median progression-free interval of 4.2 months with chemotherapy improved to 7.0 months with olaparib monotherapy (HR = 0.58; 95 % CI: 0.43-0.80; p = 0.0009) [32, 33] . No statistically significant improvement in overall survival was found between the two randomization arms in the study (HR = 0.90; 95 % CI: 0.63-1.29; p = 0.57) [32] . Subgroup analysis found no clinically relevant differences between groups [32 -34] . Anemia and neutropenia were the most commonly reported side effects of treatment with olaparib, with respective rates of 16.4 % (grade 3 and 4) and 9.3 % (grade 3 und 4); however rates of anemia and neutropenia were even higher with chemotherapy (26.4 and 49.5 %) [32] . Given this clinically relevant benefit of monotherapy with the PARP inhibitor compared to chemotherapy, approval is eagerly anticipated as it appears to offer a further promising treatment option for this special cohort of patients.
The ABRAZO trial, a study which also had a number of participating German centers, evaluated the benefits of PARP inhibitor talazoparib to treat patients with germline BRCA1/2 mutations, with the results presented at the 2017 ASCO conference [35] . ABRAZO is a single-arm study with 2 cohorts. One cohort recruited patients who showed a response to platinum-based chemotherapy in the metastatic setting and the other cohort consisted of patients who had received 3 or more chemotherapies in a metastatic setting but had not received platinum-based treatment. The median PFS of cohort 1 was 4 months (95 % CI: 2.8-5.4 months), while the median PFS of cohort 2 was 5.6 months (95 % CI: 5.5-7.8 months) [35] . Once again, the most commonly reported side effects of this PARP inhibitor were anemia (grade 3 and 4 in 16 % of patients) and neutropenia (grade 3 and 4 in 6 %). In addition, grade 3/4 thrombocytopenia was reported for 10 % of patients [35] .
The importance of PARP inhibitors compared to platinumbased therapies was evaluated in the Brightness study, with new data presented at the ESMO 2017 conference [36] . This neoadjuvant study compared 634 patients with triple-negative breast cancer (BRCA mutation was not an inclusion criteria) in three treatment arms: paclitaxel followed by doxorubicin + cyclophosphamide vs. paclitaxel and carboplatin followed by doxorubicin + cyclophosphamide vs. paclitaxel + carboplatin + veliparib followed by doxorubicin + cyclophosphamide. The pCR rates for the three regimens were 31.0 vs. 57.5 vs. 53.2 % [36] , although the difference between the two therapies which included carboplatin was not statistically significant and the addition of veliparib did not result in any improvement in the pCR rate and is therefore currently not recommended (p = 0.357).
Patient selection based on molecular changes and the type of previous platinum-based therapy appears to play an important role in treatments with PARP inhibitors. Achieving a better understanding of which patients are best suited to receive particular therapies will be extremely important to successfully establish these therapies in clinical practice. It is still not clear, for example, what role other genes currently being evaluated in panel gene tests may play. It is known, for example, that ATM, CHEK2, PALB2, BARD1 and RAD51D play a similar role to that of BRCA1 and BRCA2 in the repair of DNA double-strand breaks. Mutations occur in breast cancer with a frequency that indicates that it would be useful to take these mutations into consideration when treating patients with breast cancer [37, 38] . The importance of other lowpenetrance cancer predisposition genes has not yet entered into therapy planning. A recent publication which carried out a genome-wide association study of more than 122 000 cases with breast cancer and more than 105 000 controls was able to show that the low-penetrance variants identified to date make up around 18 % of the familial risk for breast cancer [39] . Some of these variants are particularly common in patients with triplenegative breast cancer [40 -43] .
Immuno-Oncology
The KEYNOTE-173 trial, presented at the ASCO 2017 conference, has been evaluating the checkpoint inhibitor pembrolizumab in two cohorts in a neoadjuvant setting. With 10 patients each per treatment cohort (no randomization), this study provides initial data on pCR rates following chemotherapy combined with the anti-PD-1 antibody pembrolizumab [44] . Treatment with nabpaclitaxel followed by doxorubicin and cyclophosphamide in combination with pembrolizumab resulted in complete remission of all tumor cells in 50 % of patients. The pCR rate for a chemotherapy regimen which additionally included carboplatin (in combination with nab-paclitaxel) was 80 % [44] .
The KEYNOTE-086 trial studied patients with triple-negative metastatic breast cancer who had been previously treated in the metastatic setting and had tested positive for PD-L1 in the tumor. The analysis of the results for 52 patients was available at the time of presenting the poster. With a median follow-up time of 7 months, 15 patients (29 %) were still receiving monotherapy with pembrolizumab [45] .
Even though these two studies found no persisting side effects, it is importance to establish treatment of new types of side effects in routine clinical practice. Particularly neuroendocrine side effects require better training of medical staff to make innovative therapies safer in clinical practice.
Biosimilars
With the expiry of the patent for trastuzumab, a number of biosimilar studies of anti-HER2 antibodies were presented at this yearʼs conferences [46 -52] . Four different antibodies are expected to be introduced in Germany in 2018. A neoadjuvant setting is the most common scenario used to test biosimilars. The presented studies are summarized in ▶ Table 1 . In all studies biosimilars were evaluated for their equivalence to trastuzumab in terms of the pCR rates achieved. None of the studies reported any difference in their profile of side effects or any other more common side effects compared to trastuzumab [46 -52] .
One study on PF-05280014 reported on its use in 707 patients as a first-line treatment for metastatic breast cancer. The reported progression-free 1-year survival was 52 % for trastuzumab and 56 % for PF-05280014. The profile of side effects for PF-05280014 was similar to that of trastuzumab [48] .
Patient Management
Physicians have long focused on compliance and the management of side effects in endocrine therapy in both adjuvant and metastatic settings [53 -55] . As new endocrine combination therapies are being developed, attention has once again begun to focus on these issues. As we move into the digital age, research has also begun to look at new ways of involving patients in their medical care. A prospective randomized study which recruited patients receiving chemotherapy for advanced breast cancer or genitourinary, gynecological or lung cancer (n = 766) showed that the use of internet-based monitoring improved overall survival [56] . The patients who were randomized into the intervention arm were asked to self-report on twelve common symptoms before and after hospital visits using a web-based monitoring system. In the other randomization arm, side effects were only recorded in accordance with standard clinical care. The authors reported a significantly better overall survival (HR: 0.832; 95 % CI: 0.696-0.995) following self-reporting using a web-based system. The study also found fewer emergency room visits and hospitalizations in the group using the self-reporting system [56] .
It is not yet clear which mechanisms resulted in the higher survival rates reported in their study. However, it is known that side effects can have an impact on therapy compliance. This, in turn, could lead to a poorer prognosis. It has been reported in this context that untreated side effects result in poorer compliance, particularly in endocrine therapies [54, 57, 58] .
A few study concepts in Germany have been proposed to evaluate the potential benefits of electronic medical technologies (eHealth) which use modern internet-based systems to support patients. The PreCycle study will be randomizing patients receiving palbociclib into two groups: one group will use a web-based interaction tool (CANKADO) and one group will receive standard care [59] . The PRAEGNANT study and the Seraphina study will also be investigating the impact of paper-based and web-based patient-reported outcomes (PRO) for patients with metastatic breast cancer [60 -64] .
Conclusion
With the introduction of CDK4/6 inhibitors, PARP inhibitors and immunotherapies, new classes of substances have been approved for treatment or are in advanced stages of clinical development. As for all substances which are just starting to be introduced into routine clinical practice, the question arises to what extent it will be possible to identify patients who would particularly benefit from these new therapies and which patients might need to be particularly protected from side effects. In the next few years, it will hopefully be possible to establish clinical or molecular predictors for some of these substances which will help physicians weigh up the options.
▶ Table 1 Antibodies which have been tested as biosimilars for trastuzumab. 
